Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease
| Autor: | Ursula Schreiter-Gasser, Lorena R. R. Gianotti, Dietrich Lehmann, Pascal L. Faber, Kieko Kochi, Roberto D. Pascual-Marqui, G. Künig |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty genetic structures Phenylcarbamates Rivastigmine Audiology Electroencephalography Central nervous system disease chemistry.chemical_compound Degenerative disease Alzheimer Disease Image Processing Computer-Assisted medicine Humans Aged Aged 80 and over Cerebral Cortex Pharmacology medicine.diagnostic_test Cognition Middle Aged medicine.disease Acetylcholinesterase Functional imaging Neuroprotective Agents chemistry Female Cholinesterase Inhibitors Alzheimer's disease 150 Psychology Cognition Disorders Psychology Neuroscience Psychomotor Performance medicine.drug |
| Zdroj: | Gianotti, Lorena; Künig, Gabriella; Faber, Pascal L; Lehmann, Dietrich; Pascual-Marqui, Roberto D; Kochi, Kieko; Schreiter-Gasser, Ursula (2008). Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology, 198(3), pp. 323-332. Springer 10.1007/s00213-008-1111-1 |
| DOI: | 10.1007/s00213-008-1111-1 |
| Popis: | OBJECTIVE The objective of the study is to investigate the electrocortical and the global cognitive effects of 3 months rivastigmine medication in a group of mild to moderate Alzheimer's disease patients. MATERIALS AND METHODS Multichannel EEG and cognitive performances measured with the Mini Mental State Examination in a group of 16 patients with mild to moderate Alzheimer's Disease were collected before and 3 months after the onset of rivastigmine medication. RESULTS Spectral analysis of the EEG data showed a significant power decrease in the delta and theta frequency bands during rivastigmine medication, i.e., a shift of the power spectrum towards 'normalization'. Three-dimensional low resolution electromagnetic tomography (LORETA) functional imaging localized rivastigmine effects in a network that includes left fronto-parietal regions, posterior cingulate cortex, bilateral parahippocampal regions, and the hippocampus. Moreover, a correlation analysis between differences in the cognitive performances during the two recordings and LORETA-computed intracortical activity showed, in the alpha1 frequency band, better cognitive performance with increased cortical activity in the left insula. CONCLUSION The results point to a 'normalization' of the EEG power spectrum due to medication, and the intracortical localization of these effects showed an increase of cortical activity in frontal, parietal, and temporal regions that are well-known to be affected in Alzheimer's disease. The topographic convergence of the present results with the memory network proposed by Vincent et al. (J. Neurophysiol. 96:3517-3531, 2006) leads to the speculation that in our group of patients, rivastigmine specifically activates brain regions that are involved in memory functions, notably a key symptom in this degenerative disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|